Bioactivity of mackerel peptides on obesity and insulin resistance,an in-vivo study

Of many metabolic irregularity risk factors,glucose intolerance,insulin resistance,and abdominal obesity are the main ones.The risk of vascular diseases and cancers is rather high in such individuals therefore its treatment and prevention are equally important for the health of population.Marine including fish biopeptides have frequently shown to prevent and or ameliorate these risk factors.In our earlier studies,Atlantic mackerel hydrolysate and its fractions showed promising effects on immunity and hypertension.We,therefore,in the current study,aimed to examine the effects of mackerel hydrolysate along its cationic peptides,isolated at pH3 using electrodialysis with ultrafiltration membrane,on metabolic disorder factors in diet-induced insulin resistant obese mice.Mice were fed the chow and or the hypercaloric diet (high fat high sucrose) for the duration of 8-weeks.Subsequently the hypercaloric fed insulin resistant obese mice were gavaged daily either the vehicle and or the test material at the dosage of 208 mg of sample protein per kg mice body weight.According to our observations,mackerel peptides could not effectively modulate food intake,weight gain,adiposity,plasma glucose and insulin concentrations,hepatic cholesterol,and triglyceride levels.Thus,obesity and metabolic impairments could not be averted by the treatments in insulin resistant obese mice.In conclusion,anti-hypertensive,and immunomodulatory attributes of mackerel peptides at the tested concentrations do not seem to be correlated with its metabolic syndrome benefiting effects.To presume a general statement about the metabolic syndrome benefiting potency of Atlantic mackerel's biopeptides further research is warranted.